Sarepta Therapeutics | SRPT - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 270.57M 450K 2026-09
Agios Pharmaceuticals USD 155.3M 24.53M 2026-06
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
Amgen USD 5.69B 6B 2026-09
BioCryst Pharmaceuticals USD -397.38M 517.17M 2026-09
Biogen USD 2.32B 663.6M 2026-09
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Capricor Therapeutics USD 29.16M 2.87M 2025-12
Daiichi Sankyo JPY 483.8B 5.85B 2026-09
Eli Lilly USD 10.52B 496M 2026-06
Gilead Sciences USD 13.04B 9.09B 2026-09
Incyte USD 5.64B 4.67B 2026-09
Insmed USD 606.26M 79.46M 2026-09
Ionis Pharmaceuticals USD 373M 2.76M 2026-09
Moderna USD 1.18B 223M 2026-09
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 89B 3.81B 2026-09
PTC Therapeutics USD 211.54M 15.12M 2026-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Roche Holding CHF 18.9B 2.12B 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 10.51B 598M 2026-09
Sarepta Therapeutics USD 390.39M 2.43M 2026-09
Tectonic Therapeutic USD 24.22M 3.08M 2026-06
Ultragenyx Pharmaceutical USD 283M 6M 2026-09
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09